Last update Aug. 23, 2021
Very Low Risk
Retinoic acid form of vitamin A.
Indicated in the treatment of acne and other skin diseases (psoriasis).
Topical administration on damaged skin in the form of gel, cream or 0.01-01% alcoholic solution.
At the date of the last update, there was no available published data on its excretion in breast milk.
Its pharmacokinetic data (large volume of distribution, high percentage of protein binding, low pKa and short half-life) make it unlikely that it will pass into breast milk in a clinically significant quantity.
The small dose and poor plasma absorption of most topical dermatological preparations make it unlikely that a significant amount will pass into breast milk.
Percutaneous absorption of tretinoin is less than 2% (AEMPS 2020, Valeant 2012, Akhavan 2003, van Hoogdalem 1998) and plasma levels are undetectable (Lucek 1985).
Various medical societies, expert authors and expert consensus consider the use of this medication safe or probably safe during breastfeeding (Hale, Briggs 2015, Butler 2014, Kong 2013, Leachman 2006).
Do not apply to the breast area or clean well before breastfeeding.
Systemic, oral use (as an antineoplastic) is absolutely contraindicated during lactation.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM